Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
New findings from Harvard University in the area of gene therapy described
September 16th, 2008
According to a study from the United States, "Retroviral-mediated delivery of the P140K mutant 06 -methylguanine-DNA methyltransferase (MGMT(P140K)) into hematopoietic stem cells (HSC) has been proposed as a means to protect against dose-limiting myelosuppressive toxicity ensuing from chemotherapy combining O-6-alkylating agents (e.g., temozolomide) with pseudosubstrate inhibitors (such as O-6 -benzylguanine) of endogenous MGMT. Because detoxification of O-6-alkylguanine adducts by MGMT is stoichiometric, it has been suggested that higher levels of MGMT will afford better protection to gene-modified HSC." "However, accomplishing this goal would potentially be in...
Source: Cancer Weekly (2008-09-16)
|
